Literature DB >> 10601965

Pheochromocytoma in Italy: a multicentric retrospective study.

M Mannelli1, L Ianni, A Cilotti, A Conti.   

Abstract

OBJECTIVE: To conduct an epidemiological study on pheochromocytoma in Italy.
METHODS: Data on 284 patients with pheochromocytoma observed between 1978 and 1997 were collected from 18 Italian centers through a questionnaire reporting epidemiological, clinical, laboratory, radiological and surgical data.
RESULTS: 53.6% of the patients were females and 46.4% were males. Thirty-two tumors were discovered as incidental adrenal masses. The most frequent referred symptoms were palpitations (58.1%), headache (51.9%), sweating (48. 8%) and anxiety (35.3%). Their association was present only in 15.5% of patients. Paroxysmal symptoms were reported in 67.1% and hypertensive crises in 59.7% of patients. Normal blood pressure (systolic and diastolic) was present both in the supine and upright positions in 21.1% of patients. Among laboratory assays, urinary vanylmandelic acid (VMA) was the most widely used (58.1%) and was the least sensitive (25% of false negative results). Basal plasma catecholamines were found to be normal in 11.3% of patients but were always elevated when sampled during a hypertensive paroxysm. A clonidine suppression test was performed in 38 patients with no adverse side effects. It gave a false negative response in 2 patients. A glucagon test was performed in 21 patients. It was interrupted for acute hypertension in 52.4% of patients. Only 5/21 patients were normotensive and had normal basal plasma catecholamines. In these patients the test gave a positive response in four (80%). CT (79.6%) and I-MIBG scintigraphy (68.5%) were the most widely used methods for tumor localization. CT sensitivity was 98.9% for intra-adrenal and 90.9% for extra-adrenal tumors. MIBG sensitivity was 88.5%. In the 263 patients who underwent surgery, the tumor was intra-adrenal in 89.4%, extra-adrenal in 8.5%, intra- and extra-adrenal in 2.1%, and bilateral in 11.0% of patients. Malignancy was reported in 9.9% of cases. Surgery caused remission of hypertension in 59.3%, improvement in 26.8%, and no changes in 13. 9% of patients. In the last group the interval between initial symptoms and diagnosis was significantly longer.
CONCLUSIONS: The present study confirms that the clinical presentation of pheochromocytoma is variable and aspecific. Normotension is often present and often the tumor is discovered incidentally. An indication for the routine use of screening methods more sensitive than urinary VMA is strongly suggested. The clonidine test was found to be safe and should be preferred to the glucagon test which has to be restricted to very selected patients. CT and MIBG scintigraphy are almost always successful in localizing the tumor. Reversal of hypertension by surgery seems to depend on an early diagnosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10601965     DOI: 10.1530/eje.0.1410619

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  44 in total

Review 1.  Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma.

Authors:  G Eisenhofer; T T Huynh; M Hiroi; K Pacak
Journal:  Rev Endocr Metab Disord       Date:  2001-08       Impact factor: 6.514

Review 2.  New roles of carboxypeptidase E in endocrine and neural function and cancer.

Authors:  Niamh X Cawley; William C Wetsel; Saravana R K Murthy; Joshua J Park; Karel Pacak; Y Peng Loh
Journal:  Endocr Rev       Date:  2012-03-07       Impact factor: 19.871

3.  Pheochromocytoma: a permanent challenge for the clinical endocrinologist.

Authors:  M Mannelli
Journal:  J Endocrinol Invest       Date:  2003-05       Impact factor: 4.256

Review 4.  Diagnosis and management of pheochromocytoma during pregnancy.

Authors:  M Mannelli; D Bemporad
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

5.  Images of pheochromocytoma in adrenal glands.

Authors:  Shaunagh McDermott; Colin J McCarthy; Michael A Blake
Journal:  Gland Surg       Date:  2015-08

6.  Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience.

Authors:  Montserrat Ayala-Ramirez; Lei Feng; Mouhammed A Habra; Thereasa Rich; Paxton V Dickson; Nancy Perrier; Alexandria Phan; Steven Waguespack; Shreyaskumar Patel; Camilo Jimenez
Journal:  Cancer       Date:  2011-10-17       Impact factor: 6.860

7.  Improvement of preoperative management in patients with adrenal pheochromocytoma.

Authors:  Jiang Li; Chang-Hai Yang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

8.  Detecting pheochromocytoma: defining the most sensitive test.

Authors:  Ulrich Guller; Joe Turek; Steve Eubanks; Elizabeth R Delong; Daniel Oertli; Jerome M Feldman
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

Review 9.  Pheochromocytoma/Paraganglioma: Is This a Genetic Disorder?

Authors:  Lauren Fishbein
Journal:  Curr Cardiol Rep       Date:  2019-07-31       Impact factor: 2.931

10.  [An incidental finding of retrocaval extraadrenal pheochromocytoma].

Authors:  Katharina Maria Bretterbauer; Daniela Colleselli; Ahmed Magdy; Günter Janetschek; Michael Mitterberger
Journal:  Wien Med Wochenschr       Date:  2015-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.